Companies

Who we bring together sets us apart

Companies

    Our tenants span the life science sector, including therapeutics, diagnostics, medical devices, and research tools. They learn from and support each other, often forming partnerships.

    Scientists working
    Overview

    Get to know our tenants, the
    hardworking innovators at the
    core of our community.

    View our job listings

    Tenant Spotlights

     View all spotlights

    Learn more about
    their stories

    aikium

    Tenant Spotlight on Aikium: A Trillion Shots at Targeting Tangled Proteins

    Aikium has essentially invented a new protein family. Called “SeqR” proteins, they are sequence specific binders that can be applied to different therapeutic needs such as cancer, neuro-inflammation, and some autoimmune disorders. Aikium is going after chemokine receptors, a subset of G-protein coupled receptors, a large class of molecules that have long proven difficult to target. By virtue of being on immune cells, they are front and center in cancer and immune-mediated diseases. Read post
    RVB cells delivering protein therapy continuously on skin

    NIH Awards ResVita Bio a $2M Phase II SBIR Grant for Continuous Protein Therapy for Netherton Syndrome

    ResVita Bio is pioneering continuous protein therapy, delivered through a genetically engineered probiotic platform that temporarily colonizes the skin and continuously releases therapeutic proteins, such as LEKTI, to inhibit protease activity. This continuous delivery method ensures high levels of the therapeutic agent at the site of damage, restoring the integrity of the skin barrier. This represents a significant shift from traditional therapies, which may not provide sustained treatment at the site of the disease. Read post
    David Hochschild of the California Energy Commission

    Launch of Bakar ClimatEnginuity Hub Unites UC Berkeley Climate Tech Community

    “Berkeley’s different from Las Vegas: what starts here does not end here,” said Dan Kammen, a UC Berkeley professor of energy and founding director of the Renewable and Appropriate Energy Laboratory, in his keynote address at the symposium to launch the Bakar ClimatEnginuity Hub (BCH), Berkeley’s innovation center and incubator for climate technology. BCH will accelerate the commercialization of new technologies, sending them forth to be adopted by humanity across the world as we adapt to and combat climate change. Read post
    Illustration of genetic sequence of zinc finger domains

    ARIZ Precision Medicine Announces Grant of Key US Patent Covering Lead Cancer Drug

    ARIZ has a proprietary ligand targeted nanoparticle drug delivery system designed to destroy cancer cells, without harming normal cells. ARIZ’s target a family of genes known as the PRDMs (Positive Regulatory Domain-containing Methyltransferases) that are genetic drivers that control cell growth, proliferation, survival and mobility. Studies show that alterations in the expression and activity of the PRDMs are among the first drivers in normal cells that lead to cancer cell formation. The PRDMs have been implicated in solid tumors such as breast, colon, gastric, liver, lung, melanoma, and prostate cancers, as well as in blood cancers such as leukemia, lymphoma and myeloma. Read post
    The Bakar ClimatEnginuity Hub, expected to open during the 2027-2028 academic year, will provide a home for entrepreneurs in the burgeoning field of climate technology. The donor-funded facility will be located on the west side of campus at the site currently occupied by University Hall. Rendering by Gensler

    Bakar Climate Tech Incubator Recruiting Director of BD & Partnerships

    The Director of Business Development and Partnerships of BCH will be responsible for developing highly innovative new programs and partnerships with local, national and international public and private entities to create and support a vibrant ecosystem that accelerates startup companies focused on the translation of scientific discoveries into solutions in the energy and climate tech marketplace. Read post
    positivo accepts award

    Positivo Biotechnology Wins Cystic Fibrosis Foundation’s 2024 Golden Ticket Contest

    Positivo Biotechnology has won the Cystic Fibrosis Foundation’s “Golden Ticket” Competition for their groundbreaking technology that may be the key to the next generation of treatments for cystic fibrosis. The company will receive one year of free office and lab space at Bakar Labs and access to the Cystic Fibrosis Foundation’s network of resources to develop genetic therapies for cystic fibrosis. Read post
    Scientist
    Want to learn more?

    Become a tenant at Bakar Labs

    Get in touch